In the last trading session, 0.98 million Affimed N.V. (NASDAQ:AFMD) shares changed hands as the company’s beta touched 1.98. With the company’s per share price at $0.41 changed hands at $0.04 or 9.46% during last session, the market valuation stood at $60.48M. AFMD’s last price was a discount, traded about -480.49% off its 52-week high of $2.38. The share price had its 52-week low at $0.22, which suggests the last value was 46.34% up since then. When we look at Affimed N.V.’s average trading volume, we note the 10-day average is 0.74 million shares, with the 3-month average coming to 542.90K.
Analysts gave the Affimed N.V. (AFMD) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.22. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended AFMD as a Hold, 8 felt it is a Buy and 0 rated the stock as Underweight. Affimed N.V.’s EPS for the current quarter is expected to be -$0.19.
Affimed N.V. (NASDAQ:AFMD) trade information
Instantly AFMD was in green as seen at the end of in last trading. With action 27.40%, the performance over the past five days has been green. The jump to weekly highs of 0.4061 on Friday, 11/17/23 added 9.46% to the stock’s daily price. The company’s shares are showing year-to-date downside of -67.34%, with the 5-day performance at 27.40% in the green. However, in the 30-day time frame, Affimed N.V. (NASDAQ:AFMD) is 12.06% up. Looking at the short shares, we see there were 2.16 million shares sold at short interest cover period of 4.18 days.
The consensus price target for the stock as assigned by Wall Street analysts is $5.31, meaning bulls need an upside of 92.28% from its current market value. According to analyst projections, AFMD’s forecast low is $0.92 with $12.00 as the target high. To hit the forecast high, the stock’s price needs a -2826.83% plunge from its current level, while the stock would need to soar -124.39% for it to hit the projected low.
Affimed N.V. (AFMD) estimates and forecasts
Data shows that the Affimed N.V. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -62.50% over the past 6 months, a -28.57% in annual growth rate that is considerably lower than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Affimed N.V. will rise 20.80%, while the growth in revenue is estimated to hit 26.10% for the next quarter. Year-over-year growth is forecast to reach -77.90% down from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of $1.69 million. 4 analysts are of the opinion that Affimed N.V.’s revenue for the quarter ending Mar 2024 will be $1.77 million. The company’s revenue for the corresponding quarters a year ago was $12.08 million and $5.06 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -86.00%. The estimates for the next quarter sales put growth at -65.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 4.02%. The 2023 estimates are for Affimed N.V. earnings to decrease by -21.93%.
Affimed N.V. is expected to release its next quarterly earnings report on November 14.
Affimed N.V. (NASDAQ:AFMD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.70% of Affimed N.V. shares while 54.26% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 56.94%. There are 54.26% institutions holding the Affimed N.V. stock share, with 683 Capital Management LLC the top institutional holder. As of Jun 29, 2023, the company held 6.03% of the shares, roughly 9.0 million AFMD shares worth $5.38 million.
Baker Brothers Advisors, LLC holds the second largest percentage of outstanding shares, with 4.42% or 6.6 million shares worth $3.95 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Aug 30, 2023 were iShares NASDAQ Biotechnology ETF and Vanguard Explorer Fund, Inc.. With 0.92 million shares estimated at $0.5 million under it, the former controlled 0.61% of total outstanding shares. On the other hand, Vanguard Explorer Fund, Inc. held about 0.51% of the shares, roughly 0.76 million shares worth around $0.45 million.